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Introduction. Nitric oxide (NO) is an endothelium-derived relaxing factor which plays a role in atherogenetic events.
Polymorphisms in the endothelial NO synthase gene (eNOS) influences the functional activity of the enzyme and affect the
susceptibility to atherogenesis. In this study we determined whether T-786C, G894T and 4a/4b eNOS genetic variants may
increase the susceptibility to carotid atherosclerosis.
Methods. The study groups included 304 consecutive patients with severe carotid stenosis ($70%) and 544 control
subjects. The eNOS polymorphisms were analysed by molecular biology techniques.
Results. The genotype distribution and allele frequency of eNOS 4a/4b, but not T-786C and G894T, polymorphism was
significantly different between patients and controls. Using logistic regression with adjustment for other risk factors, the 4a
allele and the combined genotype 4a4a þ 4a4b/894TT þ GT and -786CC þ TC/894TT þ GT were associated with carotid
stenosis (OR ¼ 1.5, p ¼ 0.02; OR ¼ 1.8, p ¼ 0.01; OR ¼ 1.5, p ¼ 0.04, respectively). In a subset of patients (30 of 304)
with no traditional risk factors for atherosclerosis, a relatively high incidence of the 4a allele and 4a4a þ 4a4b/-786CC þ TC
combined genotype was noted.
Discussion. Our findings suggest that the 4a allele and the eNOS combined genotypes are independent predisposing factors
to carotid atherosclerosis.
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Introduction
Atherosclerosis is a complex disease caused by an
interaction between genetic and environmental fac-
tors. Endothelial dysfunction is a key step in both
initiation and progression of atherogenesis.1 Nitric
oxide (NO) has an ability to modulate most of the steps
believed to be important in atherogenesis. For
example, NO inhibits platelet aggregation,2 leukocyte
adhesion,3 smooth muscle cell migration and prolifer-
ation4 and oxidation of atherogenic low-density
lipoproteins.5 Dysfunction in NO release or action
may therefore promote atherogenesis by inhibiting
these protective effects.
Common polymorphisms in gene encoding for
endothelial NO synthase (eNOS) influence the
expression and functional activity of the enzyme
and, in turn, might affect the susceptibility to
atherogenesis. A point mutation of guanine to
thymine, G894T (also called Glu298Asp) in exon 7 of
the eNOS gene has been described; it has been
demonstrated that this polymorphism is associated
with reduced basal NO production.6 Evidence that this
polymorphism is associated with carotid athero-
sclerosis has been reported7 but controversial results
were obtained in other Caucasian populations.8 – 10
Another variant, resulting from a thymidine being
replaced by a cytosine at nucleotide -786 (T-786C), has
been identified in the 50-flanking region of the eNOS
gene.11 This variant, which results in a reduction in the
eNOS gene promoter activity, has been associated with
carotid artery stenosis in Italians.10 Finally, a 27-base
pair (bp) repeat polymorphism, 4a/4b, at intron 4 of
the eNOS gene has been associated with altered
plasma NO levels12 and has been found to be
responsible for variations in the genetic control of
plasma nitrite and nitrate levels.13 No association
between this polymorphism and carotid athero-
sclerosis in asymptomatic Italians was observed.7
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The aim of the study was to investigate if there was




The study population consisted of 316 unrelated
consecutive patients admitted to the Department of
Vascular Surgery of the University of Florence with
severe carotid stenosis and 544 unrelated healthy
subjects recruited from the staff of the University of
Florence and from partners or friends of patients. We
used a structured questionnaire to identify disease-
free controls and to exclude subjects who were
suspected of having any form of vascular disease.
Consanguineous subjects were excluded; patients
and controls were Caucasian and drawn from the
same area (Central Italy). All subjects gave informed
consent and the study complies with the Declaration
of Helsinki and was approved by the local ethics
committee of the Faculty of Medicine, University of
Florence.
Carotid stenosis was assessed as severe ($70%) by
duplex scanning with colour coded echo flow imaging
and confirmed by angioCT, according to the NASCET
criteria.14 Preoperative neurological symptoms, defined
as ipsilateral cerebrovascular events during 180 days
within the intervention, were recorded in 112 patients;
the remaining 192 patients were asymptomatic. Patients
with non-hemispheric symptoms were considered to be
asymptomatic. All patients underwent a clinical cardi-
ological evaluation, ECG and echocardiogram and
peripheral arteries echo color Doppler analysis. In
patients with symptoms suggestive of ischemic heart
disease, further investigations were performed (ECG on
exercise stress testing, myocardial scintigraphy, and
coronary angiography). Twelve patients have been
excluded because of having abdominal aortic aneurysm.
The study group included 304 patients.
Controls were defined as subjects who had no carotid
stenosis detectable by ultrasound duplex scanning
powered by colour-coded echo flow imaging.
Hypertension was defined as systolic pressure
$140 mmHg and/or diastolic pressure $90 mmHg
according to The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure;15 dyslipidemia was
defined according to the Third report of the National
Cholesterol Education Program (NCEP).16 Diabetes
was defined in agreement with the American Diabetes
Association.17
Genetic analysis
eNOS polymorphisms were analysed after genomic
DNA extraction from peripheral blood leukocytes
using a QIAmp Blood Kit (QIAGEN, Hilden,
Germany). The eNOS T-786C polymorphism was
analysed by PCR-RFLP analysis as previously
described.11 The eNOS 4a/4b polymorphism was
analyzed by PCR-amplification according to Gonzalez-
Ordonez et al.18 The eNOS G894T polymorphism
detection has been performed by real-time fluor-
escence PCR through Light Cycler instrument (Roche
Diagnostics).19
Statistical analysis
Statistical analysis was performed using SPSS
(Chicago, USA) for Windows (Version 11.5, Copy-
rightq SPSS Inc.). The x2-test was used to test for
deviation of genotype distribution from Hardy–
Weinberg equilibrium. Established risk factors for
atherosclerosis were identified by univariate logistic
regression analysis. The relationship between genetic
variables and carotid atherosclerosis was determined
by multivariate logistic regression analysis after
adjustment for traditional risk factors. A p-value
,0.05 was considered to indicate statistical signifi-
cance. The analysis was based on a dominant model of
inheritance.
Results
Demographic and clinic characteristics and the preva-
lence of the atherosclerotic traditional risk factors in
patients and controls are reported in Table 1. Genotype
distributions were in Hardy–Weinberg equilibrium in
patients and controls for all eNOS polymorphisms.
The genotype distribution and allele frequencies of the
eNOS gene T-786C, G894T and 4a/4b polymorphisms
in patients and controls are shown in Table 2. No
significant difference in eNOS T-786C and G894T
polymorphisms genotype distribution and allele fre-
quency was observed between patients and controls
(Table 2). The eNOS 4a/4b genotype distribution and
allele frequency were significantly different between
patients and controls (Table 2). When we assumed a
dominant model of inheritance, an association
between the 4a allele and an increased predisposition
to the disease was observed (OR 4a4a þ 4a4b vs.
4b4b ¼ 1.55 95% CI 1.15–2.08, p ¼ 0:004); no associ-
ation between the -786C and 894T allele and carotid
stenosis predisposition was found (OR-786CC þ TC
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vs. -786TT ¼ 1.03 95% CI 0.72 – 1.46, p ¼ 0:9;
OR894TT þ GT vs. GG ¼ 1.02 95% CI 0.72–1.43, p ¼
0:9; respectively).
The odds ratios for the contemporary presence of the
4a and 894T alleles and of the -786C and 894T variants
were 1.6 (95% CI 1.1–2.4, p ¼ 0:009) and 1.2 (95% CI 0.9–
1.6, p ¼ 0:1), respectively. By using multivariate
analysis, eNOS 4a allele and the combined genotype
4a4a þ 4a4b/894TT þ GT and -786CC þ TC/894TT þ
GTwere associated with carotid stenosis (Fig. 1). The 4a
allele was associated with carotid stenosis (OR
4a4a þ 4a4b vs. 4b4b ¼ 1.9 95% CI 1.2–2.9, p ¼ 0:003
and OR4a4a þ 4a4b vs. 4b4b ¼ 1.6 95% CI 1.1–2.3,
p ¼ 0:008, respectively) but not with symptoms.
In 30 out of 304 patients (9.8%) no traditional
risk factors for atherosclerosis were found. In this
sub-group a significantly higher percentage of
patients were homozygous for the 4a variant in
comparison to those with one or more traditional
risk factors (16.6% vs. 3.6%, respectively, p ¼ 0:007)
and a higher eNOS 4a allele frequency (0.30 vs
0.22, p ¼ 0:12) were observed. The eNOS
4a4a þ 4a4b/-786CC þ TC, but not the other
eNOS combined genotypes, was more frequent in
this subgroup of patients in comparison to patients
with traditional risk factors (40% vs. 28.5%,
respectively).
When patients with other localizations of athero-
sclerotic diseases (coronary artery disease and chronic
obstructive peripheral arteriopathy) were excluded
from the analysis, a significant difference in genotype
distribution and allele frequency of eNOS 4a/4b, but
not of eNOS T-786C and G894T polymorphisms
between patients and controls was found (Table 3).
From the univariate and multivariate analysis a
significant association between the eNOS 4a allele and
an increased predisposition to carotid atherosclerosis
was observed (OR 4a4a þ 4a4b vs. 4b4b ¼ 1.68 95% CI
1.18–2.39 p ¼ 0:004; OR 4a4a þ 4a4b vs. 4b4b ¼ 1.6 95%
CI 1.02–2.4 p ¼ 0:04; respectively).
Discussion
This is the first report in which eNOS T-786C, G894T
and 4a/4b polymorphisms are analyzed in a Cauca-
sian population affected by carotid atherosclerosis.
Our findings document a high prevalence of the eNOS
4a allele and combined genotypes in patients who
have carotid artery stenosis. The 4a/4b polymorphism
is associated with altered plasma NO levels, influen-
cing both NO and enzyme production13 and data from
literature reported that it accounted for 25% of the
variance of NO circulating levels.12 Impaired NO
function may contribute to the development of
atherosclerosis. NO inhibits vascular smooth muscle
cells proliferation, platelet adhesion/aggregation and
leukocyte and monocyte adhesion. Moreover, NO






Age (years)* 72 (33–80) 71 (24–81)
Males, n (%) 212 (70) 372 (68)
Females, n (%) 92 (30) 172 (32)
Hypertension, n (%) 182 (60) 164 (30)
Diabetes, n (%) 56 (18) 22 (4)
Dyslipidemia, n (%) 170 (56) 106 (19)
Smoking habit, n (%) 198 (65) 108 (20)
BMI (kg/m2) (%)† 25.8 ^ 3.5 24.8 ^ 3.8
Familial history for
cardiovascular disease n (%)
114 (37) 42 (8)
BMI, body mass index.
*Median and range.
†Mean ^ standard deviations.
Table 2. Genotype distribution and allele frequencies of the eNOS polymorphisms
Genotype Allele Patients ðn ¼ 304Þ n (%) Controls ðn ¼ 544Þ n (%) p-value
-786CC 56 (18) 84 (15)
-786TC 147 (48) 260 (48)
-786TT 101 (33) 200 (37) 0.42
C 0.43 0.39 0.19
894TT 46 (15) 58 (11)
894GT 130 (43) 248 (46)
894GG 128 (42) 238 (44) 0.16
T 0.37 0.33 0.20
4a4a 15 (5) 14 (3)
4a4b 104 (34) 138 (25)
4b4b 185 (61) 392 (72) 0.002
4a 0.22 0.15 0.0004
-786CC, homozygotes for the -786C allele; -786TC, heterozygotes; -786TT, homozygotes for the -786T allele; 894TT, homozygotes for the 894T
allele; 894GT, heterozygotes; 894GG, homozygotes for the 894G allele; 4a4a, homozygotes for the 4a allele; 4a4b, heterozygotes; 4b4b,
homozygotes for the 4b allele.
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induces tissue factor expression and ability of lym-
phocyte to form coaggregates with platelets. The
presence of rare variants in the eNOS gene may
contribute to reduce NO levels; infact, it has been
demonstrated that the polymorphisms investigated
alter NOS activity and reduce basal NO production,
contributing in plaque progression and
atherothrombosis.
The presence of any DNA rare variant, such as
eNOS 4a allele, which affects NO levels or NOS
activity might promote pathological changes in
vessel wall morphology associated with carotid
atherosclerosis. The observation that the eNOS
4a4b polymorphism affects carotid stenosis also in
patients with no traditional risk factors, supports
the evidence of a genetic contribution to the
pathogenesis of the disease.
Our results are at variance with some previous
studies,7,10 but in keeping with others,8 – 9,20 which
demonstrated no association between the G894T and
T-786C polymorphisms and carotid atheroma. These
different results are likely a consequence not only of
different sample size, but also, most importantly,
of different selection criteria adopted for patients and
controls, in particular clinical presentation, extent of
disease, age, race, geographical area, and concomitant
environmental risk factors. In this study we investi-
gated patients with severe carotid stenosis whereas,
Lembo et al.7 focused on characterization of the early
vascular manifestations of the atherosclerotic disease
Fig. 1. Odds ratios for eNOS combined genotypes (Multivariate analysis). Adjusted for age, sex, hypertension, dyslipidemia,
diabetes, smoking habit and BMI.
Table 3. Genotype distribution and allele frequencies of eNOS polymorphisms in patients with atherosclerosis localized at carotid artery
ðn5 180Þ
Genotype Allele Patients ðn ¼ 180Þ n (%) Controls ðn ¼ 544Þ n (%) p-value
-786CC 30 (17) 84 (15)
-786TC 85 (47) 260 (48)
-786TT 65 (36) 200 (37) 0.9
C 0.40 0.39 0.7
894TT 26 (14) 58 (11)
894GT 76 (42) 248 (46)
894GG 78 (43) 238 (44) 0.4
T 0.36 0.33 0.5
4a4a 9 (5) 14 (3)
4a4b 62 (34) 138 (25)
4b4b 109 (61) 392 (72) 0.01
4a 0.22 0.15 0.002
-786CC, homozygotes for the -786C allele; -786TC, heterozygotes; -786TT, homozygotes for the -786T allele; 894TT, homozygotes for the 894T
allele; 894GT, heterozygotes; 894GG, homozygotes for the 894G allele; 4a4a, homozygotes for the 4a allele; 4a4b, heterozygotes; 4b4b,
homozygotes for the 4b allele.
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and involved a high percentage of hypertensive
patients.
In conclusion, the findings of this study suggest that
the eNOS polymorphisms may influence the predis-
position to carotid atherosclerosis. In this study we
have found that eNOS 4a rare variant was associated
with carotid atherosclerosis in patients without other
risk factors for atherosclerosis. Similar prevalence of
this polymorphism has been observed in studies
considering coronary artery disease by Hwang J.J.21
and by us.22
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